Anna Sapino

Dr. Anna Sapino

Department of Medical Sciences, University of Turin, 10126 Turin, Italy
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2020 in Histopathology
Verified
Journal Article
Open access
PDF file
PTPuay Hoon Tan
Puay Hoon Tan
IEIan Ogilvie Ellis
Ian Ogilvie Ellis
KAKimberly Allison
Kimberly Allison
EBEdi Brogi
Edi Brogi
SFStephen B Fox
Stephen B Fox
FBfor the WHO Classification of Tumours Editorial Board
for the WHO Classification of Tumours Editorial Board
The newly published World Health Organization (WHO) Classification of Tumours of the breast features significant changes compared to earlier editions. In this review, we outline the major changes in this important reference source for those diagnosing tumours, or engaged in cancer research, and describe the significant changes. For breast cancer, the overview acknowledges the treatment‐relevant subtypes of invasive carcinoma (based on ER and HER2 status) and new data is added to support the differences in pathogenesis, treatment response and prognosis of these clinically relevant groupings. The WHO Classification of Tumours is increasingly evidence‐based, with a clear update cycle, improved quality of illustrations, as well as content, led by an editorial board comprising pathologists, but increasingly incorporating input from other disciplines. The advent of the new website allows the use of whole slide images, and hyperlinks to evidence or external bodies that produce guidance on staging or reporting.

1 November 2011 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ABAndrea Bertotti
Andrea Bertotti
GMGiorgia Migliardi
Giorgia Migliardi
FGFrancesco Galimi
Francesco Galimi
FSFrancesco Sassi
Francesco Sassi
DTDavide Torti
Davide Torti
LTLivio Trusolino
Livio Trusolino
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine. We produced large xenograft cohorts from 85 patient-derived, genetically characterized metastatic colorectal cancer samples (“xenopatients”) to discover novel determinants of therapeutic response and new oncoprotein targets. Serially passaged tumors retained the morphologic and genomic features of their original counterparts. A validation trial confirmed the robustness of this approach: xenopatients responded to the anti-EGFR antibody cetuximab with rates and extents analogous to those observed in the clinic and could be prospectively stratified as responders or nonresponders on the basis of several predictive biomarkers. Genotype–response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases. Importantly, HER2 amplification was also enriched in clinically nonresponsive KRAS wild-type patients. A proof-of-concept, multiarm study in HER2-amplified xenopatients revealed that the combined inhibition of HER2 and EGFR induced overt, long-lasting tumor regression. Our results suggest promising therapeutic opportunities in cetuximab-resistant patients with metastatic colorectal cancer, whose medical treatment in the chemorefractory setting remains an unmet clinical need. Significance: Direct transfer xenografts of tumor surgical specimens conserve the interindividual diversity and the genetic heterogeneity typical of the tumors of origin, combining the flexibility of preclinical analysis with the informative value of population-based studies. Our suite of patient-derived xenografts from metastatic colorectal carcinomas reliably mimicked disease response in humans, prospectively recapitulated biomarker-based case stratification, and identified HER2 as a predictor of resistance to anti-epidermal growth factor receptor antibodies and of response to combination therapies against HER2 and epidermal growth factor receptor in this tumor setting. Cancer Discovery; 1(6); 508–23. ©2011 AACR. Read the Commentary on this article by Ciardiello and Normanno, p. 472 This article is highlighted in the In This Issue feature, p. 457

12 December 2002 in Oncogene
Verified
Journal Article
Closed access
PDF file
EDEswaran Devarajan
Eswaran Devarajan
ASAysegul A Sahin
Aysegul A Sahin
JCJack S Chen
Jack S Chen
RKRaghu R Krishnamurthy
Raghu R Krishnamurthy
NANeeraj Aggarwal
Neeraj Aggarwal
KMKapil Mehta
Kapil Mehta

1 July 2021 in Seminars in Cancer Biology
Verified
Journal Article
Open access
Caterina MarchiòCaterina Marchiò
Caterina Marchiò
LALaura Annaratone
Laura Annaratone
DMDra. Ana Marques
Dra. Ana Marques
LCLaura Casorzo
Laura Casorzo
EBEnrico Berrino
Enrico Berrino
Anna SapinoAnna Sapino
Anna Sapino
The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of other anti-HER2 compounds. Pioneering works on HER2-positive breast cancer in the 90s' launched a new era in clinical research and oncology practice that has reshaped the natural history of this disease. In diagnostic pathology the HER2 status is routinely assessed by using a combination of immunohistochemistry (IHC, to evaluate HER2 protein expression levels) and in situ hybridization (ISH, to assess HER2 gene status). For this purpose, international recommendations have been developed by a consensus of experts in the field, which have changed over the years according to new experimental and clinical data. In this review article we will document the changes that have contributed to a better evaluation of the HER2 status in clinical practice, furthermore we will discuss HER2 heterogeneity defined by IHC and ISH as well as by transcriptomic analysis and we will critically describe the complexity of HER2 equivocal results. Finally, we will introduce the clinical impact of HER2 mutations and we will define the upcoming category of HER2-low breast cancer with respect to emerging clinical data on the efficacy of specific anti-HER2 agents in subgroups of breast carcinomas lacking the classical oncogene addition dictated by HER2 amplification.

1 August 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
Andrea Sartore-BianchiAndrea Sartore-Bianchi
Andrea Sartore-Bianchi
FPFilippo Pietrantonio
Filippo Pietrantonio
SLSara Lonardi
Sara Lonardi
BMBenedetta Mussolin
Benedetta Mussolin
FRFrancesco Rua
Francesco Rua
ABAlberto Bardelli
Alberto Bardelli
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS/BRAF/EGFR mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab (ClinicalTrials.gov: NCT03227926; EudraCT 2016-002597-12). The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy. In CHRONOS, patients with tissue-RAS WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint of the trial was met; and, of 27 enrolled patients, eight (30%) achieved partial response and 17 (63%) disease control, including two unconfirmed responses. These clinical results favorably compare with standard third-line treatments and show that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting.

19 August 2004 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
GCGábor Cserni
Gábor Cserni
Dario GregoriDario Gregori
Dario Gregori
FMF. Merletti
F. Merletti
Anna SapinoAnna Sapino
Anna Sapino
MMMaria Piera Mano
Maria Piera Mano
GBG. Bussolati
G. Bussolati